EH3 Stock Chart & Stats
€11.80
€0.10(0.85%)
At close: 4:00 PM EDT
€11.80
€0.10(0.85%)
Day’s Range― - ―
52-Week Range€11.20 - €17.20
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€259.69M
Enterprise Value€22.31
Total Cash (Recent Filing)€314.65M
Total Debt (Recent Filing)€5.25M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Nov 04, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding21,122,835
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)1.36
P/FCF Ratio42.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€156.01M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe total revenues included a $25M upfront payment from the Recordati deal, contributing to the overall revenue growth.
Strategic PartnershipsThe Recordati partnership in Europe helps reshape Amarin's business model by transferring commercialization to a seasoned local partner with established cardiovascular infrastructure and expertise.
Bears Say
Competition ChallengesThe longer-term outlook for the US Vascepa business remains conservative given growing pressure from generic competitors.
Market CompetitionInvestors may remain cautious about the commercial business as the US VASCEPA franchise continues to face significant pressure from at least eight generic competitors.
Amarin News
EH3 FAQ
What was Amarin Corporation Plc’s price range in the past 12 months?
Amarin Corporation Plc lowest stock price was €11.20 and its highest was €17.20 in the past 12 months.
What is Amarin Corporation Plc’s market cap?
Amarin Corporation Plc’s market cap is €259.69M.
When is Amarin Corporation Plc’s upcoming earnings report date?
Amarin Corporation Plc’s upcoming earnings report date is Nov 04, 2026 which is in 91 days.
How were Amarin Corporation Plc’s earnings last quarter?
Amarin Corporation Plc released its earnings results on Jul 29, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of -€0.009 by -€0.009.
Is Amarin Corporation Plc overvalued?
According to Wall Street analysts Amarin Corporation Plc’s price is currently Overvalued.
Does Amarin Corporation Plc pay dividends?
Amarin Corporation Plc does not currently pay dividends.
What is Amarin Corporation Plc’s EPS estimate?
Amarin Corporation Plc’s EPS estimate is -0.02.
How many shares outstanding does Amarin Corporation Plc have?
Amarin Corporation Plc has 21,122,835 shares outstanding.
What happened to Amarin Corporation Plc’s price movement after its last earnings report?
Amarin Corporation Plc reported an EPS of -€0.017 in its last earnings report, missing expectations of -€0.009. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amarin Corporation Plc?
Currently, no hedge funds are holding shares in DE:EH3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amarin Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:EH3 Sentiment 80%
Sector Average 64%
Sector Average 64%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.51%
Trailing 12-Months
Company Description
Amarin Corporation Plc
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
EH3 Company Deck
EH3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of constructive operational and financial improvements alongside transitional revenue headwinds. Amarin emphasized strong international volume growth (59% global, 69% Europe under Recordati), completion of restructuring with material cost savings, improved cash generation and a stronger balance sheet. At the same time, reported revenue declined year-over-year due to a prior-year upfront payment and the shift to a partnered European model, COGS increased 22%, and certain geographies remain early with reimbursement timing risks. Management's commentary was optimistic about the trajectory, highlighting sequential European revenue gains, narrowing operating losses and ongoing positive cash flow.View all DE:EH3 earnings summaries